Quantum Helium Limited (QHE) provided shareholders with a review of the key milestones achieved over the past twelve months ahead of the Company’s Extraordinary General Meeting (“EGM”), which is scheduled to
Quantum Helium Limited (QHE) provided shareholders with a review of the key milestones achieved over the past twelve months ahead of the Company’s Extraordinary General Meeting (“EGM”), which is scheduled to
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold, WTI
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are for the FTSE 100, DAX, Dow, Bitcoin,
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are for the FTSE 100, DAX, Dow, Bitcoin,
Zenith Energy Ltd. (ZEN) announced the appointment of Mr. Charles Michel, the former President of the European Council (2019-2024) and former Prime Minister of Belgium (2014-2019), to further strengthen the legal
The AIM All-Share slipped slightly on the week and is now down around 7% year-to-date, underlining the pressure on smaller companies. In contrast, the FTSE 100 closed the week at
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold,
ImmuPharma PLC (IMM), the specialist drug discovery and development company, provided an update on its auto-immune technology platform program, P140. IMM said “The receipt of the first Combined Search and Examination
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold,
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
Another year on AIM is drawing to a close, and with it comes a familiar reminder: backing the market’s smallest companies is not for the faint-hearted — but the rewards